NEW YORK, NY--(Marketwire - August 21, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Swedish Medical Center in Englewood, Colorado, has joined Delcath’s Phase III clinical trial for the treatment of metastatic melanoma in the liver. Swedish Medical Center is the ninth center to join this multi-center trial testing the Company’s Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan.